

09/817748
Search results

Refine Search

Search Results -

Terms	Documents
L9 and attenuat\$	6

Database:

US Pre-Grant Publication Full-Text Database
 US Patents Full-Text Database
 US OCR Full-Text Database
 EPO Abstracts Database
 JPO Abstracts Database
 Derwent World Patents Index
 IBM Technical Disclosure Bulletins

Search:

Refine Search

Recall Text

Clear

Interrupt

Search History

DATE: Saturday, July 10, 2004 [Printable Copy](#) [Create Case](#)

<u>Set Name</u> side by side	<u>Query</u>	<u>Hit Count</u>	<u>Set Name</u> result set
	<i>DB=PGPB,USPT,USOC,EPAB,JPAB,DWPI,TDBD; PLUR=YES; OP=OR</i>		
<u>L10</u>	L9 and attenuat\$	6	<u>L10</u>
<u>L9</u>	l3 and (Th1 or Th2 or IL near 4 or "IL-4")	22	<u>L9</u>
	<i>DB=PGPB; PLUR=YES; OP=OR</i>		
<u>L8</u>	US-20020197711-A1.did.	1	<u>L8</u>
	<i>DB=PGPB,USPT,USOC,EPAB,JPAB,DWPI,TDBD; PLUR=YES; OP=OR</i>		
<u>L7</u>	attenuat\$ near10 (CVB or coxsackievirus\$ or group near B near coxsackievirus\$)	8	<u>L7</u>
<u>L6</u>	L5 and Th1 and Th2	3	<u>L6</u>
<u>L5</u>	L4 and (IL near 4 or "IL-4")	4	<u>L5</u>
<u>L4</u>	attenuat\$ near10 (CVB or coxsackievirus\$ or group near B near coxsackievirus\$) near10 vector\$	6	<u>L4</u>
<u>L3</u>	(CVB or coxsackievirus\$ or group near B near coxsackievirus\$) near10 vector\$	42	<u>L3</u>

<u>L2</u>	(CVB or coxsackievirus\$ or group near B near coxsackievirus\$)near10 vector\$	42	<u>L2</u>
<u>L1</u>	(CVB or coxsackievirus\$ or group near B near coxsackievirus\$)	1665	<u>L1</u>

END OF SEARCH HISTORY

[Generate Collection](#)[Print](#)**Search Results - Record(s) 1 through 42 of 42 returned.**

-
- ☐ 1. 20040072739. 27 Feb 01. 15 Apr 04. Compositions and methods for regulating endogenous inhibitor of ATP synthase, including treatment for diabetes. Anderson, Christen M., et al. 514/12; 435/7.2 A61K038/17 G01N033/53 G01N033/567.
-
- ☐ 2. 20040029278. 17 May 02. 12 Feb 04. Eukaryotic layered vector initiation systems. Dubensky, Thomas W. JR., et al. 435/456; 435/320.1 435/325 C12N015/861 C12N015/86.
-
- ☐ 3. 20030232058. 17 Mar 03. 18 Dec 03. Recombinant alphavirus-based vectors with reduced inhibition of cellular macromolecular synthesis. Dubensky, Thomas W. JR., et al. 424/186.1; 435/235.1 435/456 514/44 536/23.72 A61K039/12 C07H021/02 C12N007/00 C12N015/86.
-
- ☐ 4. 20030232035. 16 Jan 03. 18 Dec 03. Eukaryotic layered vector initiation systems. Dubensky, Thomas W. JR., et al. 424/93.2; 435/320.1 435/325 435/456 435/6 800/8 A01K067/00 C12Q001/68 A61K048/00 C12P021/02 C12N005/06 C12N015/86.
-
- ☐ 5. 20030190329. 26 Mar 01. 09 Oct 03. Coxsackievirus vectors and their use in prevention and treatment of disease. Tracy, Steven M., et al. 424/208.1; 424/216.1 A61K039/21 A61K039/125 C12N015/867.
-
- ☐ 6. 20030166593. 30 Apr 02. 04 Sep 03. Non-viral vesicle vector for cardiac specific gene delivery. Chien, Kenneth, et al. 514/44; 435/320.1 435/455 A61K048/00 C12N015/74 C12N015/85.
-
- ☐ 7. 20030099619. 25 Nov 02. 29 May 03. Method and composition for targeting an adenoviral vector. Wickham, Thomas J., et al. 424/93.2; 435/235.1 435/325 435/456 435/5 530/350 A61K048/00 C12Q001/70 C12N015/861 C07K014/705 C07K014/075.
-
- ☐ 8. 20030096397. 18 Feb 00. 22 May 03. Recombinant alphavirus-based vectors with reduced inhibition of cellular macromolecular synthesis. Schlesinger, Sondra, et al. 435/320.1; 435/69.1 435/91.1 435/91.2 C12P021/06 C12P019/34 A61K031/665 A01N057/00 C12N015/00 C12N015/09 C12N015/63 C12N015/70 C12N015/74.
-
- ☐ 9. 20030026781. 27 Feb 02. 06 Feb 03. Compositions and methods for regulating endogenous inhibitor of ATP synthase, including treatment for diabetes. Anderson, Christen Marie, et al. 424/85.5; 435/18 C12Q001/34 A61K038/21.
-
- ☐ 10. 20020197711. 12 Jun 01. 26 Dec 02. Coxsackievirus B4 expression vectors and uses thereof. Ramsingh, Arlene I., et al. 435/320.1; 424/148.1 424/199.1 424/207.1 435/5 435/69.7 435/91.1 435/91.33 C12Q001/70 C12P021/04 C12P019/34 A61K039/42 A61K039/12 A61K039/21 C12N015/00 C12N015/09 C12N015/63 C12N015/70 C12N015/74.
-
- ☐ 11. 20020164598. 03 May 01. 07 Nov 02. Method for evaluating and applying an individual's genetic characteristics to determine response to cardiovascular medication therapy. Muhlestein, Joseph B., et al. 435/6; 702/20 705/3 C12Q001/68 G06F017/60 G06F019/00 G01N033/48 G01N033/50.
-
- ☐ 12. 20020137213. 30 May 01. 26 Sep 02. Adenovirus particles with mutagenized fiber proteins. Hallenbeck, Paul L., et al. 435/456; 435/235.1 530/350 C12N015/861 C12N005/06 C12N007/00

C07K014/075.

-
- ☐ 13. 20020058045. 01 May 01. 16 May 02. Adenovirus vector. Mizuguchi, Hiroyuki, et al. 424/233.1; 424/199.1 424/93.21 435/235.1 435/320.1 435/456 A61K048/00 C12N007/01 C12N015/861 A01N063/00 A61K039/12 A61K039/23 A61K039/235 C12N007/00 C12N015/00 C12N015/09 C12N015/63 C12N015/70 C12N015/74 C12N015/86.
-
- ☐ 14. 20020049176. 27 Feb 01. 25 Apr 02. Modulation of mitochondrial mass and function for the treatment of diseases and for target and drug discovery. Anderson, Christen M., et al. 514/44; A61K048/00.
-
- ☐ 15. 6649396. 03 Feb 00; 18 Nov 03. Fiber receptor-independent system for the propagation of adenoviral vectors. Curiel; David T., et al. 435/235.1; 435/326 435/455 435/69.3. C12N007/01 C12N005/06 C12N005/16 C12N015/09 C12N015/85 C12N015/86.
-
- ☐ 16. 6592874. 18 Feb 00; 15 Jul 03. Recombinant alphavirus-based vectors with reduced inhibition of cellular macromolecular synthesis. Schlesinger; Sondra, et al. 424/218.1; 424/219.1 435/235.1 435/236. A61K039/193.
-
- ☐ 17. 6514695. 20 Jan 00; 04 Feb 03. Compositions and methods for intraductal gene therapy. Barsky; Sanford H., et al. 435/6; 435/320.1 435/455 536/23.1. C12Q001/68 C12N015/63 C12N015/85 C07H021/04.
-
- ☐ 18. 6465634. 08 Oct 99; 15 Oct 02. Recombinant alphavirus-based vectors with reduced inhibition of cellular macromolecular synthesis. Dubensky, Jr.; Thomas W., et al. 536/23.72; 435/320.1. C07H021/04.
-
- ☐ 19. 6458560. 08 Oct 99; 01 Oct 02. Recombinant alphavirus-based vectors with reduced inhibition of cellular macromolecular synthesis. Dubensky, Jr.; Thomas W., et al. 435/69.1; 435/457. C12P021/06.
-
- ☐ 20. 6451592. 06 Oct 97; 17 Sep 02. Recombinant alphavirus-based vectors with reduced inhibition of cellular macromolecular synthesis. Dubensky, Jr.; Thomas W., et al. 435/320.1; 435/69.1 435/69.3 435/69.51 435/69.52. C12N015/00 C12N015/19 C12N015/24.
-
- ☐ 21. 6426196. 08 Oct 99; 30 Jul 02. Alphavirus structural protein expression cassettes. Dubensky, Jr.; Thomas W., et al. 435/69.1; 536/23.72. C12P021/06 C07H021/04.
-
- ☐ 22. 6391632. 08 Oct 99; 21 May 02. Recombinant alphavirus-based vectors with reduced inhibition of cellular macromolecular synthesis. Dubensky, Jr.; Thomas W., et al. 435/325; 435/457 435/69.1 536/23.72. C12N005/10.
-
- ☐ 23. 6376236. 22 Jan 99; 23 Apr 02. Recombinant alphavirus particles. Dubensky, Jr.; Thomas W., et al. 435/320.1; C12N015/63.
-
- ☐ 24. 6342372. 08 Jul 99; 29 Jan 02. Eukaryotic layered vector initiation systems for production of recombinant proteins. Dubensky, Jr.; Thomas W., et al. 435/69.1; 435/455 536/23.2 536/23.72 536/24.1. C12N005/16 C12N015/11 C12N015/33.
-
- ☐ 25. 6323024. 27 Mar 00; 27 Nov 01. Coxsackie virus vectors for delivery of nucleic acids encoding antigenic or therapeutic products. Tracy; Steven M., et al. 435/320.1; 424/93.1 424/93.2

424/93.6 435/235.1 435/366 435/455 435/456 435/69.1 536/23.5 536/23.51 536/23.52 536/24.1.
C12N015/86 C12N015/63 C12N015/19 C07H021/04.

☐ 26. 6245966. 19 Mar 99; 12 Jun 01. Adenoviral mediated gene transfer into lymphocytes. DeGregori; James. 800/18; 435/320.1 435/325 435/455 435/456 800/21 800/22 800/25 800/3 800/8. C12N015/09 C12N015/63 C12N015/00 C12N005/00.

☐ 27. 6237129. 27 Mar 98; 22 May 01. Method for constraining circuit element positions in structured layouts. Patterson; Cameron D., et al. 716/8; 716/10 716/17. G06F017/50 H03K017/693.

☐ 28. 6210921. 12 Sep 97; 03 Apr 01. CAR: a novel coxsackievirus and adenovirus receptor. Finberg; Robert W., et al. 435/69.1; 435/252.3 435/254.11 435/320.1 435/325 530/350 536/23.1 536/23.5. C12N015/00.

☐ 29. 6071742. 05 Mar 97; 06 Jun 00. Coxsackie virus as a vector for delivery of anti-inflammatory cytokines. Tracy; Steven M., et al. 435/320.1; 536/23.5 536/23.51 536/23.52. C12N015/86.

☐ 30. 6015694. 16 Sep 97; 18 Jan 00. Method for stimulating an immune response utilizing recombinant alphavirus particles. Dubensky, Jr.; Thomas W., et al. 435/69.3; 424/199.1 424/204.1 424/228.1 424/234.1 424/265.1 424/274.1 424/277.1 536/23.5 536/23.7 536/23.72. C12P021/06.

☐ 31. 6015686. 15 Mar 95; 18 Jan 00. Eukaryotic layered vector initiation systems. Dubensky, Jr.; Thomas W., et al. 435/69.1; 435/320.1 435/325 435/410 435/455 435/456 536/23.5 536/23.72 536/24.1. C12P021/02 C12N015/00 C12N015/63 C12N015/11.

☐ 32. 5843723. 30 Oct 96; 01 Dec 98. Alphavirus vector constructs. Dubensky, Jr.; Thomas W., et al. 435/69.3; 435/235.1 435/320.1 435/325. C12P021/02 C12N015/63 C12N005/10.

☐ 33. 5814482. 30 Oct 96; 29 Sep 98. Eukaryotic layered vector initiation systems. Dubensky, Jr.; Thomas W., et al. 435/69.3; 435/320.1 536/23.1 536/24.1. C12P021/00 C12N015/86 C07H021/04.

☐ 34. 5789245. 30 Oct 96; 04 Aug 98. Alphavirus structural protein expression cassettes. Dubensky, Jr.; Thomas W., et al. 435/320.1; 435/325 435/69.1 536/23.72. C12N015/63 C12N015/40 C12N005/10 C12P021/02.

☐ 35. 5736388. 30 Dec 94; 07 Apr 98. Bacteriophage-mediated gene transfer systems capable of transfecting eukaryotic cells. Chada; Sunil, et al. 435/320.1; 424/93.6 435/235.1 514/44. C12N015/85 C12N015/88 A61K048/00.

☐ 36. 5721133. 01 Jun 95; 24 Feb 98. Protease assays. Dasmahapatra; Bimalendu. 435/252.3; 435/23 536/23.4. C12N001/21 C12Q001/37.

☐ 37. 5623685. 01 Dec 94; 22 Apr 97. Vector register validity indication to handle out-of-order element arrival for a vector computer with variable memory latency. Leedom; George W., et al. 712/9; 712/5. G06F009/38 G06F012/06.

☐ 38. 5572235. 02 Nov 92; 05 Nov 96. Method and apparatus for processing image data. Mical; Robert J., et al. 345/600; 345/629 345/634. G09G005/02.

☐ 39. 5103478. 12 Oct 90; 07 Apr 92. Secure management of keys using control vectors with multi-path checking. Matyas; Stephen M., et al. 380/280; 380/43 713/172. H04L009/32 G06F007/04.

☐ 40. US20030190329A. New vaccine comprising a viral vector having a modified coxsackievirus genome, useful for immunizing an individual against a virus or for preventing, treating or suppressing onset of insulin-dependent diabetes mellitus. CHAPMAN, N M, et al. A61K039/125 A61K039/21 C12N015/867.

☐ 41. WO 200192549A. Adenoviral coat protein which permits production of adenoviral vectors that bind and infect host cells not naturally infected by adenovirus, comprises various non-native ligands. BROUGH, D E, et al. A61K035/76 A61K048/00 A61P035/00 C07K014/075 C07K014/705 C07K014/75 C12N005/10 C12N007/00 C12N007/02 C12N015/09 C12N015/86 C12N015/861 C12Q001/02 C12Q001/70.

☐ 42. EP 396894A. Secure management of keys multi-path control vector checking - executing requested cryptographic function only if control vector checking succeeds at each of multiple interconnected cryptographic devices. ABRAHAM, D G, et al. G06F007/04 G07F007/10 G09C001/00 H04L009/08 H04L009/32.

[Generate Collection](#)[Print](#)

Terms	Documents
(CVB or coxsackievirus\$ or group near B near coxsackievirus\$) near10 vector\$	42

[Prev Page](#)[Next Page](#)[Go to Doc#](#)



Day : Saturday
Date: 7/10/2004

Time: 14:33:22

Inventor Name Search

Enter the **first few letters** of the Inventor's Last Name.
Additionally, enter the **first few letters** of the Inventor's First name.

Last Name

First Name

To go back use Back button on your browser toolbar.

Back to [PALM](#) | [ASSIGNMENT](#) | [OASIS](#) | [Home page](#)



PALM INTRANET

Day : Saturday
Date: 7/10/2004

Time: 14:33:22

Inventor Name Search

Enter the **first few letters** of the Inventor's Last Name.
Additionally, enter the **first few letters** of the Inventor's First name.

Last Name

First Name

To go back use Back button on your browser toolbar.

Back to [PALM](#) | [ASSIGNMENT](#) | [OASIS](#) | [Home page](#)